Experts and Doctors on diabetic retinopathy in Sweden
Topic: diabetic retinopathy
Lind M, Oden A, Fahlen M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia. 2010;53:1093-8 pubmed publisher
..Clinical trials should preferably be designed for long periods or include patients with low previous glycaemic exposure to distinguish trial effects from those of the metabolic memory. ..
Lindenberger M, Olsen H, Länne T. Impaired compensatory response to hypovolaemic circulatory stress in type 1 diabetes mellitus. Diab Vasc Dis Res. 2011;8:136-42 pubmed publisher
..Furthermore, type 1 diabetes patients present with impaired capillary fluid absorption, which in combination with potentially decreased sympathetic vasoconstriction impedes cardiovascular homeostasis during acute hypovolaemic stress. ..
Agardh E, Bruun A, Agardh C. Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes. Curr Eye Res. 2001;23:276-84 pubmed
..The numbers of retinal pigment epithelial cells and cells in the ganglion cell layer were unaffected both by age and diabetes. ..
Gokturk C, Garpenstrand H, Nilsson J, Nordquist J, Oreland L, Forsberg Nilsson K. Studies on semicarbazide-sensitive amine oxidase in patients with diabetes mellitus and in transgenic mice. Biochim Biophys Acta. 2003;1647:88-91 pubmed
Leksell J, Sandberg G, Wikblad K. Self-perceived health and self-care among diabetic subjects with defective vision: a comparison between subjects with threat of blindness and blind subjects. J Diabetes Complications. 2005;19:54-9 pubmed
..A great challenge in future research in diabetes is to implement education programs suitable especially for patients who have gone blind because of diabetes. ..
Heintz E, Wirehn A, Peebo B, Rosenqvist U, Levin L. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia. 2010;53:2147-54 pubmed publisher
..Approximately one-third of patients with diabetes have some form of DR. Average healthcare costs increase considerably with the severity of DR, which suggests that preventing progression of DR may lower healthcare costs. ..
Hard A, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review. Acta Paediatr. 2011;100:1523-7 pubmed publisher
..Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible adverse effects on VEGF-dependent development must be considered. ..
Björkqvist J, Jämsä A, Renne T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost. 2013;110:399-407 pubmed publisher
..Targeting PK offers novel strategies not previously appreciated to interfere with thrombosis and vascular inflammation in a broad variety of diseases. ..
Grönvall Nordquist J, Bäcklund L, Garpenstrand H, Ekblom J, Landin B, Yu P, et al
. Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus. J Diabetes Complications. 2001;15:250-6 pubmed
..99) than in those without retinopathy (mean 1.78), 95% CI for difference 0.1-1.5 microg mg(-1). The results of the present study are compatible with a role for SSAO in the development of diabetic retinopathy. ..